Treatment of Clostridium difficile infection.

Clostridium difficile infection: epidemiology, risk factors and management. Nat Rev Gastroenterol Hepatol (2010) 2.61

Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis (2013) 2.22

Chenodeoxycholate is an inhibitor of Clostridium difficile spore germination. J Bacteriol (2008) 1.53

Stability of Vancomycin 25 mg/mL in Ora-Sweet and Water in Unit-Dose Cups and Plastic Bottles at 4°C and 25°C. Can J Hosp Pharm (2010) 1.40

Outcome of ICU patients with Clostridium difficile infection. Crit Care (2012) 1.38

Surface layers of Clostridium difficile endospores. J Bacteriol (2011) 1.22

Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes (2010) 1.19

Clostridium difficile infection. Am J Med Sci (2010) 1.17

Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16

Clostridium difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol Res Pract (2011) 1.11

Culturing and maintaining Clostridium difficile in an anaerobic environment. J Vis Exp (2013) 1.05

Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol (2016) 1.01

The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci (2009) 1.00

Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother (2012) 0.98

New advances in the treatment of Clostridium difficile infection (CDI). Ther Clin Risk Manag (2008) 0.98

Clostridium difficile infection and inflammatory bowel disease: understanding the evolving relationship. World J Gastroenterol (2010) 0.97

The membrane as a target for controlling hypervirulent Clostridium difficile infections. J Antimicrob Chemother (2012) 0.96

Medical microbiology: A toxin contest. Nature (2010) 0.95

Clostridium difficile infection in Italian urban hospitals: data from 2006 through 2011. BMC Infect Dis (2013) 0.95

Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine (2011) 0.91

Prospects for flavonoid and related phytochemicals as nature-inspired treatments for Clostridium difficile infection. J Appl Microbiol (2014) 0.90

Toxic megacolon associated Clostridium difficile colitis. World J Gastrointest Endosc (2010) 0.87

Probiotics in clostridium difficile Infection. J Clin Gastroenterol (2011) 0.86

Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin. Antimicrob Agents Chemother (2014) 0.84

Infectious diarrhea: when to test and when to treat. CMAJ (2010) 0.83

Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs (2010) 0.82

Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection. Antimicrob Agents Chemother (2009) 0.82

Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations. Antimicrob Agents Chemother (2013) 0.82

Clostridium difficile-associated enteric disease after percutaneous endoscopic gastrostomy. J Gastroenterol (2009) 0.81

Clinical update for the diagnosis and treatment of Clostridium difficile infection. World J Gastrointest Pharmacol Ther (2014) 0.81

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection. Antibiotics (Basel) (2015) 0.81

Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother (2014) 0.80

Fecal transplant policy and legislation. World J Gastroenterol (2015) 0.80

MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother (2013) 0.79

The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol (2011) 0.79

Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem (2014) 0.79

Development of a microarray for identification of pathogenic Clostridium spp. Diagn Microbiol Infect Dis (2009) 0.78

The vermiform appendix and recurrent Clostridium difficile infection: a curious connection. Clin Gastroenterol Hepatol (2011) 0.78

Clinical and Microbiologic Characteristics of Clostridium difficile Infection Caused by Binary Toxin Producing Strain in Korea. Infect Chemother (2013) 0.78

Using machine-learned bayesian belief networks to predict perioperative risk of clostridium difficile infection following colon surgery. Interact J Med Res (2012) 0.77

A homology model for Clostridium difficile methionyl tRNA synthetase: active site analysis and docking interactions. J Mol Model (2010) 0.75

Iminosugar C-glycoside analogues of α-D-GlcNAc-1-phosphate: synthesis and bacterial transglycosylase inhibition. J Org Chem (2014) 0.75

Fulminant, non-antibiotic associated Clostridium difficile colitis following Salmonella gastroenteritis. J Gen Intern Med (2010) 0.75

Investigation of toxin gene diversity and antimicrobial resistance of Clostridium difficile strains. Biomed Rep (2014) 0.75

The microbiota and immune response during Clostridium difficile infection. Anaerobe (2016) 0.75

Fidaxomicin--the new drug for Clostridium difficile infection. Indian J Med Res (2015) 0.75

Management of Clostridium difficile Infection. Gastroenterol Hepatol (N Y) (2016) 0.75

Clostridium difficile: the increasingly difficult pathogen. Crit Care (2008) 0.75

Pseudomembranous colitis. Dis Mon (2015) 0.75

Current advances related to Clostridium difficile infection. Indian J Med Res (2015) 0.75

Clostridium difficile infection: a re-emerging threat. Mo Med (2009) 0.75

Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. BMJ Case Rep (2011) 0.75

An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection. PLoS One (2017) 0.75

An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med (2005) 18.10

Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63

Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis (2008) 3.50

Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. J Clin Microbiol (2006) 2.52

tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol (2006) 2.49

Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol (2007) 2.06

Measures to control and prevent Clostridium difficile infection. Clin Infect Dis (2008) 2.04

Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother (2008) 2.03

Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis (2011) 2.02

Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother (2009) 1.94

Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis (2013) 1.58

High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis (2009) 1.41

Guidelines and quality for community-acquired pneumonia: measures from the Joint Commission and the Centers for Medicare and Medicaid Services. Am J Health Syst Pharm (2009) 1.38

Co-production of NDM-1 and OXA-232 by Klebsiella pneumoniae. Emerg Infect Dis (2014) 1.18

Results of survey on implementation of Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Infect Control Hosp Epidemiol (2009) 1.14

Need and potential of antimicrobial stewardship in community hospitals. Clin Infect Dis (2011) 1.12

SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol (2003) 1.07

Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg? Clin Infect Dis (2007) 1.06

Perirectal swab surveillance for Clostridium difficile by use of selective broth preamplification and real-time PCR detection of tcdB. J Clin Microbiol (2011) 1.05

Pittsburgh Regional Healthcare Initiative: a systems approach for achieving perfect patient care. Health Aff (Millwood) (2003) 1.02

Screening for Acinetobacter baumannii colonization by use of sponges. J Clin Microbiol (2010) 1.01

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother (2002) 0.91

Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Pharmacotherapy (2009) 0.89

Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am (2003) 0.89

Patient-associated risk factors for acquisition of methicillin-resistant Staphylococcus aureus in a tertiary care hospital. Infect Control Hosp Epidemiol (2010) 0.87

Invasive polyarticular septic arthritis caused by nontypeable haemophilus influenzae in a young adult: a case report and literature review. J Clin Rheumatol (2011) 0.85

Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis (2002) 0.85

Methicillin-resistant Staphylococcus aureus control: we didn't start the fire, but it's time to put it out. Infect Control Hosp Epidemiol (2006) 0.85

Another tale of two guidelines. Clin Infect Dis (2006) 0.85

Why are antibiotic-resistant nosocomial infections spiraling out of control? Infect Control Hosp Epidemiol (2005) 0.84

Clostridium difficile infection: a critical overview. Curr Infect Dis Rep (2008) 0.82

Acquisition of rectal colonization by vancomycin-resistant Enterococcus among intensive care unit patients treated with piperacillin-tazobactam versus those receiving cefepime-containing antibiotic regimens. Antimicrob Agents Chemother (2007) 0.81

Successful meropenem desensitization in a patient with cystic fibrosis. Ann Pharmacother (2003) 0.79

Fluoroquinolone-associated dysglycemias: a tale of two toxicities. Pharmacotherapy (2005) 0.76

Has methicillin-resistant Staphylococcus aureus stopped spreading in intensive care units? Clin Infect Dis (2005) 0.75

AUIC in humans: a fact-based discussion. Ann Pharmacother (2003) 0.75

Control of nosocomial methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis (2006) 0.75

Survey on influenza vaccination noncompliance among nursing students. Infect Control Hosp Epidemiol (2014) 0.75

Quality pneumonia care: distinguishing community-acquired from health care-associated pneumonia. Am J Health Syst Pharm (2009) 0.75

Stability of cefepime and metronidazole prepared for simplified administration as a single product. Diagn Microbiol Infect Dis (2006) 0.75

Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care (2002) 0.75